These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

630 related articles for article (PubMed ID: 23276521)

  • 61. Correlation between mismatch repair and survival of patients with gastric cancer after 5-FU-based adjuvant chemotherapy.
    Zhao F; Li E; Shen G; Dong Q; Ren D; Wang M; Zhao Y; Liu Z; Ma J; Xie Q; Liu Z; Li Z; Gao L; Zhao J
    J Gastroenterol; 2023 Jul; 58(7):622-632. PubMed ID: 37036516
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites.
    Zhang Y; Ma J; Zhang S; Deng G; Wu X; He J; Pei H; Shen H; Zeng S
    Int J Colorectal Dis; 2015 Sep; 30(9):1173-83. PubMed ID: 26054387
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer.
    Johnston PG; Fisher ER; Rockette HE; Fisher B; Wolmark N; Drake JC; Chabner BA; Allegra CJ
    J Clin Oncol; 1994 Dec; 12(12):2640-7. PubMed ID: 7989939
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Genotype of thymidylate synthase likely to affect efficacy of adjuvant 5-FU based chemotherapy in colon cancer.
    Matsui T; Omura K; Kawakami K; Morita S; Sakamoto J
    Oncol Rep; 2006 Nov; 16(5):1111-5. PubMed ID: 17016601
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prognostic and predictive roles of DNA mismatch repair status in colon cancer patients treated with oxaliplatin-based chemotherapy: a retrospective study.
    Qin Q; Zhou AP; Yang L; Xu C; Sun YK; Zhang W; Wang JW; Zhong DS
    J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33316771
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.
    Sinicrope FA; Mahoney MR; Smyrk TC; Thibodeau SN; Warren RS; Bertagnolli MM; Nelson GD; Goldberg RM; Sargent DJ; Alberts SR
    J Clin Oncol; 2013 Oct; 31(29):3664-72. PubMed ID: 24019539
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites.
    Johnston PG; Benson AB; Catalano P; Rao MS; O'Dwyer PJ; Allegra CJ
    J Clin Oncol; 2003 Mar; 21(5):815-9. PubMed ID: 12610179
    [TBL] [Abstract][Full Text] [Related]  

  • 68. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.
    Shirota Y; Stoehlmacher J; Brabender J; Xiong YP; Uetake H; Danenberg KD; Groshen S; Tsao-Wei DD; Danenberg PV; Lenz HJ
    J Clin Oncol; 2001 Dec; 19(23):4298-304. PubMed ID: 11731512
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer.
    de Vos tot Nederveen Cappel WH; Meulenbeld HJ; Kleibeuker JH; Nagengast FM; Menko FH; Griffioen G; Cats A; Morreau H; Gelderblom H; Vasen HF
    Int J Cancer; 2004 Apr; 109(3):468-71. PubMed ID: 14961589
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer.
    Johnston PG; Mick R; Recant W; Behan KA; Dolan ME; Ratain MJ; Beckmann E; Weichselbaum RR; Allegra CJ; Vokes EE
    J Natl Cancer Inst; 1997 Feb; 89(4):308-13. PubMed ID: 9048835
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Single nucleotide polymorphism in the 5' tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients.
    Marcuello E; Altés A; del Rio E; César A; Menoyo A; Baiget M
    Int J Cancer; 2004 Dec; 112(5):733-7. PubMed ID: 15386371
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients.
    Paradiso A; Xu J; Mangia A; Chiriatti A; Simone G; Zito A; Montemurro S; Giuliani F; Maiello E; Colucci G
    Int J Cancer; 2004 Aug; 111(2):252-8. PubMed ID: 15197779
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Should adjuvant chemotherapy be recommended to a 75-year-old woman with deficient mismatch repair (dMMR) gene product expression seen in a stage II colon adenocarcinoma with lymphovascular invasion?
    Sorscher S
    Curr Probl Cancer; 2018 Nov; 42(6):601-604. PubMed ID: 30119912
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Prognostic importance of thymidylate synthase expression in early breast cancer.
    Pestalozzi BC; Peterson HF; Gelber RD; Goldhirsch A; Gusterson BA; Trihia H; Lindtner J; Cortés-Funes H; Simmoncini E; Byrne MJ; Golouh R; Rudenstam CM; Castiglione-Gertsch M; Allegra CJ; Johnston PG
    J Clin Oncol; 1997 May; 15(5):1923-31. PubMed ID: 9164203
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy.
    Giampieri R; Maccaroni E; Mandolesi A; Del Prete M; Andrikou K; Faloppi L; Bittoni A; Bianconi M; Scarpelli M; Bracci R; Scartozzi M; Cascinu S
    Gastric Cancer; 2017 Jan; 20(1):156-163. PubMed ID: 26796888
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapy.
    Li S; Zhu L; Yao L; Xia L; Pan L
    BMC Gastroenterol; 2014 Aug; 14():154. PubMed ID: 25175730
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Thymidylate synthase genotyping is more predictive for therapy response than immunohistochemistry in patients with colon cancer.
    Gosens MJ; Moerland E; Lemmens VP; Rutten HT; Tan-Go I; van den Brule AJ
    Int J Cancer; 2008 Oct; 123(8):1941-9. PubMed ID: 18661526
    [TBL] [Abstract][Full Text] [Related]  

  • 78. LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy.
    Lou YT; Chen CW; Fan YC; Chang WC; Lu CY; Wu IC; Hsu WH; Huang CW; Wang JY
    PLoS One; 2014; 10(4):e0123973. PubMed ID: 25919688
    [TBL] [Abstract][Full Text] [Related]  

  • 79. DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer.
    Sinicrope FA
    Nat Rev Clin Oncol; 2010 Mar; 7(3):174-7. PubMed ID: 20190798
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Views of Australian Medical Oncologists Regarding the Use of Mismatch Repair Status to Assist Adjuvant Chemotherapy Recommendations for Patients With Early-Stage Colon Cancer.
    Loh KW; Michael M; Zalcberg JR; Jefford M
    Clin Colorectal Cancer; 2015 Sep; 14(3):192-7. PubMed ID: 26002619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.